Exact Sciences has launched Cancerguard, a multi-cancer early detection (MCED) blood test designed to identify over 50 cancer types by detecting circulating tumor DNA and associated proteins. Demonstrating 64% overall sensitivity and 68% for six deadly cancer types, the test is recommended annually for adults aged 50 to 84 without recent cancer history. Exact has partnered with Quest Diagnostics to offer blood collection at roughly 7,000 US sites, with payment plans and financial assistance options available.